Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use.
We report a culture-proven case of Mycobacterium bovis vertebral osteomyelitis in a 76-year-old man who had undergone intravesical BCG therapy for bladder cancer 7 years previously. He presented with debilitating back pain and had radiographic evidence of T6-7 disk space destruction with involvement of adjacent vertebrae. Tissue culture from the disk space confirmed the diagnosis of vertebral osteomyelitis due to hematogenous spread of M. bovis. Treatment with antituberculous medications was begun soon after tissue diagnosis was made, and the patient fared well with medical therapy alone. Although uncommon, this infectious complication of BCG therapy should always be considered in the appropriate clinical setting. Timely diagnosis is important, because chemotherapy, when initiated early in the disease, can preclude the necessity for surgical intervention.
Abu-Nader
Rima
R
Division of Infectious Diseases, University of Iowa Hospitals and Clinics, Iowa City, USA.
Terrell
Christine L
CL
D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009163:Mycobacterium bovis / Q000472:pathogenicity*; D010019:Osteomyelitis / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D011859:Radiography; D013904:Thoracic Vertebrae / Q000000981:diagnostic imaging*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D000995:Antitubercular Agents; D001500:BCG Vaccine